David Hoffmeister, William Knight, Kathrin Jansen, Aaron Shatkin, Doros Platika, Steven Ratoff, Susan Davidson, Edwin Moses | GenomeWeb

David Hoffmeister, last week named new chief financial officer for Invitrogen, will earn a base salary of $425,000 plus an incentive bonus, guaranteed for his first year, and a one-time signing bonus of $375,000, the company said this week in an 8-K filing with the US Securities and Exchange Commission. Hoffmeister will also receive a $224,000 employment bonus payable on or before each of the first three anniversary dates of his employment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.